Talkzone: Cardiac Risks Of Off-label Drugs To Treat COVID-19

Thursday • September 19
CST 5:01 | EST 6:01 | MST 4:01 | PST 3:01 | GMT 22:01

Other Non-Flash Media Players

Winamp, iTunes

Windows Media Player

Real Player

QuickTime

Iphone

April 08, 2020

Cardiac risks of off-label drugs to treat COVID-19

Episode Segments:


Cardiac risks of off-label drugs to treat COVID-19 A study published recently in Mayo Clinic Proceedings details information about potential cardiac side effects when using off-label drugs to treat COVID-19. Off-label means the drug has been approved by the Food and Drug Administration to treat a different condition. Some of the off-label drugs being used to treat COVID-19 have a risk of sudden cardiac arrest and death. On the Mayo Clinic Q&A podcast, Dr. Michael Ackerman, a Mayo Clinic genetic cardiologist and director of the Windland Smith Rice Sudden Death Genomics Laboratory, explains how heart monitoring is important to identify at-risk patients.

Embed Code

Mayo Clinic Q&A
Show Home Page
Healthy Living Channel
Channel Home Page
Hosted By:
Tracy McCray Dr. Tom Shives
Previous Episodes

Healthy Living Channel

Becoming Thin Within

Break The Chains

Get Waisted With Rene'

Healing Conversations

Healthy Talk Radio

Heaven Sent And Bent

Let's Talk Nutrition

Mayo Clinic Q&A

Mayo Clinic Radio

Med Clinic Radio

Personal Development Radio Show

Relationship Management

Relationship Straight Talk

Stop And Think Radio

The Business Of Medicine

The Dr. Robbins Show

The Pain-Free Zone

The Path To A Better Future

The Staying Young Radio Show